| Autor: |
Bennett CL; The Southern Network on Adverse Reactions (SONAR) Program, South Carolina College of Pharmacy, Columbia, SC, USA.; The Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.; SC Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Berger JR; Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Sartor O; Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA., Carson KR; Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA., Hrushesky WJ; The Southern Network on Adverse Reactions (SONAR) Program, South Carolina College of Pharmacy, Columbia, SC, USA.; The Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.; SC Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.; Oncology Analytics Inc, Plantation, FL, USA., Georgantopoulos P; The Southern Network on Adverse Reactions (SONAR) Program, South Carolina College of Pharmacy, Columbia, SC, USA.; The Arnold School of Public Health, University of South Carolina, Columbia, SC, USA., Raisch DW; College of Pharmacy, Pharmacoeconomics, Epidemiology, Public Policy, Outcomes Research Program, University of New Mexico, Albuquerque, NM, USA., Norris LB; The Southern Network on Adverse Reactions (SONAR) Program, South Carolina College of Pharmacy, Columbia, SC, USA., Armitage JO; The University of Nebraska Medical Center, Omaha, NE, USA. |
Plný text